Tau Interest Rising As Janssen Licenses AC Immune Alzheimer’s Vaccine
This article was originally published in The Pink Sheet Daily
AC Immune of Switzerland will work with Janssen on a therapeutic Tau-targeted vaccine for Alzheimer’s that is in Phase Ib and which could be used in combination with beta-amyloid based approaches to maximize therapeutic responses to the disease. J&J also has licensed a pioneering microbiome drug from Vedanta.
You may also be interested in...
While the company is hyping the benefit seen in a subgroup analysis of the first Phase III trial of the tau aggregation inhibitor, which failed to show an overall benefit in mild-to-moderate Alzheimer's disease, Datamonitor Healthcare analyst Maha Elsayed raises some questions.
START-UP reviews five years of fundraising and exit activities for privately held biopharma companies developing neurology treatments. Next month we’ll delve into neurology medtech and diagnostics companies’ capital-raising and bow-outs.
In addition to a spate of FDA approvals closing out the year, Roche contended with trial failures and Actavis received a “complete response” letter for its nebivolol/valsartan combination.